RecruitingNot applicableNCT06374238
Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
Studying Sickle cell anemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Pittsburgh
- Principal Investigator
- Charles Jonassaint, PhDUniversity of Pittsburgh
- Intervention
- CBT+ Health coach(behavioral)
- Enrollment
- 470 target
- Eligibility
- 16-30 years · All sexes
- Timeline
- 2025 – 2028
Study locations (14)
- University of South Alabama Medical Center, Mobile, Alabama, United States
- UCLA Mattel Children's Hospital Ronald Reagan Hospital, Los Angeles, California, United States
- Connecticut Children's Medical Center, Hartford, Connecticut, United States
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
- The Regents of the University of Michigan, Ann Arbor, Michigan, United States
- Rutgers New Jersey Medical School, Newark, New Jersey, United States
- Weil Cornell Medical College, New York, New York, United States
- University of Rochester Medical Center, Rochester, New York, United States
- Wake Forest Baptist Hospital, Durham, North Carolina, United States
- East Carolina University Health Medical Center, Greenville, North Carolina, United States
- UPMC University of Pittsburgh Classical Hematology Adult Clinic, Pittsburgh, Pennsylvania, United States
- UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
- Virginia Commonwealth University, Richmond, Virginia, United States
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06374238 on ClinicalTrials.govOther trials for Sickle cell anemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07369024Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young AdultsMohsen Saidinejad
- RECRUITINGNCT07373639A Long-term Follow-up Study in Patients Who Received BEAM-101Beam Therapeutics Inc.
- RECRUITINGNANCT07402811Mindfulness-Based Intervention for Pain and Sleep in Adolescents and Young Adults With Sickle Cell DiseaseUniversity of Illinois at Chicago
- RECRUITINGPHASE1NCT06647979Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-HemoglobinopathiesDaniel Bauer
- RECRUITINGNANCT06555939Promoting Resilience Among Adolescents and Young Adults With Sickle Cell DiseaseBoston Children's Hospital
- RECRUITINGPHASE3NCT06975865The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell DiseaseSanofi
- RECRUITINGNCT06944067Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell DiseaseNational Human Genome Research Institute (NHGRI)
- RECRUITINGNCT06923111PASS of Xromi Comparing Safety and Effectiveness in Children Under 2 Years With Sickle Cell Disease [PRECISE PASS]Nova Laboratories Limited